

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
<b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> November 21, 2016	
<b>Re.:</b> Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated November 21, 2016, titled "Zydus receives final approval from the USFDA for Metronidazole Tables", which will be produced at the group's formulations manufacturing facility at Baddi. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, Cadila Healthcare Limited



**Upen H. Shah**  
Company Secretary



**Encl.: As above**

## **Zydus receives final approval from the USFDA for Metronidazole Tablets**

*Ahmedabad, 21 November 2016*

Zydus Cadila has received the final approval from the USFDA to market Metronidazole Tablets USP in strengths of 250 mg and 500 mg. The drug which is used to treat infections caused by bacteria or parasites will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 105 approvals and has so far filed nearly 275 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*